Healthcare / Medical Instruments & SuppliesASX
$1.35
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-61000.00 · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
68/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$160M
P/E
13.5x
↓EV/EBITDA
9.3x
↓ROE
11.1%
↑Gross Margin
62.1%
↑Debt/Equity
0.43
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+10.8%
FCF CAGR
-22.4%
FCF margin
3.6%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $111.2M · net income $10.4M · FCF $4.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $111.2M | $111.2M | $107.9M | $95.2M | $81.6M |
| Net Income | $10.4M | $10.4M | $7.1M | $7.3M | $8.9M |
| EBITDA | $21.0M | $21.0M | $15.3M | $14.4M | $17.3M |
| EPS | 0.09 | 0.09 | 0.06 | 0.06 | 0.08 |
| Gross Margin | 62.1% | 62.1% | 56.8% | 55.8% | 61.5% |
| Operating Margin | 12.2% | 12.2% | 5.8% | 5.8% | 9.7% |
| Net Margin | 9.4% | 9.4% | 6.5% | 7.7% | 11.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.43 | 0.43 | 0.37 | 0.02 | 0.02 |
| Current Ratio | 3.83 | 3.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.0M | $4.0M | $-21.4M | $-61000.00 | $8.6M |
| Returns | |||||
| ROE | 11.1% | 11.1% | 8.0% | 8.7% | 11.2% |
| Valuation | |||||
| P/E | 13.50 | 13.50 | 13.80 | 13.54 | 11.84 |
| EV/EBITDA | 9.27 | 9.27 | 8.12 | 6.52 | 5.59 |
| P/B | 1.71 | 1.71 | 1.11 | 1.18 | 1.33 |
| Growth & Yield | |||||
| Revenue Growth | 3.1% | 3.1% | 13.4% | 16.5% | — |
| EPS Growth | 47.6% | 47.6% | -3.1% | -18.5% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.0%
EPS terminal req.
$0.12
Spread vs growth
36.7%
5Y implied EPS CAGR
10.6%
EPS terminal req.
$0.14
Spread vs growth
37.1%
10Y implied EPS CAGR
10.3%
EPS terminal req.
$0.23
Spread vs growth
37.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+61.3%
Start / end P/E
14.3x → 15.4x
EPS bridge
0.06 → 0.09
Residual
+3.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.